Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients

Clinical Cancer Research

Volumn 11, Issue 13, 2005, Pages 4793-4801

  Feller, Nicole ^a   Van Der Pol, Marjolein A ^a   Waaijman, Taco ^a   Weijers, Geert W D ^a   Westra, Guus ^a   Ossenkoppele, Gert J ^a   Schuurhuis, Gerrit J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CELL MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLAST CELL; BONE MARROW PURGING; CANCER DIAGNOSIS; CANCER RELAPSE; CD34 SELECTION; CELL COUNT; CELL SELECTION; CONTAMINATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; REPRODUCIBILITY; SAFETY; SURVIVAL RATE;

ACUTE DISEASE; ANTIGENS, CD; ANTIGENS, CD15; ANTIGENS, CD34; ANTIGENS, CD45; BONE MARROW PURGING; FEMALE; GLYCOPROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID; MALE; PEPTIDES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 27644591253     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0031     Document Type: Article

References (18)

1. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998;351:700-8.
2. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341:85-6.
3. Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990;75:1606-14.
4. Miller CB, Rowlings PA, Zhang MJ, et al. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol 2001;29:1336-46.
5. Miller CB, Zehnbauer BA, Piantadosi S, Rowley SD, Jones RJ. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991;78:1125-31.
6. Feller N, Jansen-van der Weide MC, van der Pol MA, Westra AH, Ossenkoppele GJ, Schuurhuis GJ. Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden. Exp Hematol 2005;33:120-30.
7. Berkahn L. Immunologic methods of purging in autologous stem cell transplantation. J Hematother Stem Cell Res 2000;9:147-59.
8. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-12.
9. Lang P, Bader P, Schumm M, et al. Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br J Haematol 2004;124:72-9.
10. Gordon PR, Leimig T, Babarin-Dorner A, et al. Large-scale isolation of CD133+ progenitor cells from G-CSF mobilized peripheral blood stem cells. Bone Marrow Transplant 2003;31;17-22.
11. Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001;97:3574-80.
12. Wuchter C, Ratei R, Spahn G, et al. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica 2001;86:154-61.
13. Thomas X, Campos L, Archimbaud E, et al. Surface marker expression in acute myeloid leukaemia at first relapse. Br J Haematol 1992;81;40-4.
14. van der Pol MA, Feller N, Roseboom M, et al. Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 2003;88:983-93.
15. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33.
16. Feller N, van der Pol MA, van Stijn A, et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004;18:1380-90.
17. van der Pol MA, Broxterman HJ, Westra G, Ossenkoppele GJ, Schuurhuis GJ. Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples. Cytometry 2003;55B:14-21.
18. To LB, Haylock DN, Dowse T, et al. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. Blood 1994;84:2330-939.